Tofogliflozin: The road goes ever on

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 9, 2014, Pages 1197-1201

  Pafili, Kalliopi ^a   Papanas, Nikolaos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Oral hypoglycaemic agents; SGLT 2 inhibitors; Tofogliflozin; Treatment; Type 2 diabetes mellitus

Indexed keywords

TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALYSIS; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GLUCOSE BLOOD LEVEL;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84901070203     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.916278     Document Type: Review

References (16)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
2. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010;19:1581-9
3. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009;11:79-88
4. Invokana. Available from: http://www. invokanahcp.com/prescribing- information.pdf [Last accessed 5 April 2014]
5. Summary of product characteristics. Available from: http://ec.europa.eu/ health/documents/community-register/2012/20121112124487/anx-124487-en. pdf [Last accessed 5 April 2014]
6. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
7. Ferrannini E. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010;33:2217-24
8. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-19
9. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6
10. List JF, Woo V, Morales E, et al. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
11. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74
12. FDA approves new diabetes drug, canagliflozin, despite CV concerns. Available from: http://www.medscape.com/viewarticle/791562 [Accessed 24 January 2014]
13. Doggrell SA, McIntyre K. Canagliflozin-something new for type 2 diabetes, but is it safe and efficacious? Expert Opin Pharmacother 2014;15:437-41
14. Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012;341:692-701
15. Tanizawa Y, kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014;15(6):749-66
16. Cherney DZ, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 2014;129:587-97